Physician profile
Sam S Ahn
NPI 1558423814
$24,784.62
in general payments reported to CMS, 2019-2025
46 companies · $4,313 in 2025
The $4,313 reported for 2025 was more than what 84% of Allergy & Immunology (Internal Medicine) providers received nationally (typical 2025 total: $681).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,162 · 2020: $1,478 · 2021: $3,106 · 2022: $8,496 · 2023: $2,807 · 2024: $3,424 · 2025: $4,313.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,758 · Consulting Fee: $2,686 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,757.81 |
| Consulting Fee | $2,685.64 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bio Products Laboratory USA, INC. | $6,962.73 | 2019-2023 | Gammaplex, Coagadex |
| Genentech USA, INC. | $3,758.58 | 2020-2025 | Xolair |
| Genzyme Corporation | $3,184.98 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $1,796.14 | 2019-2025 | Tezspire, Fasenra, Airsupra |
| Optinose US, INC. | $1,205.03 | 2019-2025 | |
| Glaxosmithkline, LLC. | $1,179.49 | 2019-2025 | Nucala, Trelegy Ellipta, Shingrix |
| Regeneron Healthcare Solutions, INC. | $792.22 | 2019-2025 | Dupixent |
| Csl Behring | $689.55 | 2020-2025 | Hizentra, Andembry, Haegarda |
| Grifols USA, LLC | $589.89 | 2021-2025 | Xembify, Prolastin-C Liquid |
| Amgen INC. | $540.47 | 2022-2025 | Tezspire, Actimmune |
| Novartis Pharmaceuticals Corporation | $461.88 | 2019-2025 | Xolair |
| Takeda Pharmaceuticals U.S.A., INC. | $419.28 | 2022-2025 | Cuvitru, Takhzyro, Eohilia |
| Pfizer INC. | $417.13 | 2019-2024 | |
| Adma Biomanufacturing LLC | $350.64 | 2023-2025 | |
| Biocryst US Sales Co., LLC | $312.98 | 2021-2025 | Orladeyo |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $254.16 | 2019-2025 | Albuterol Sulfate |
| Abbvie INC. | $215.92 | 2022-2023 | Rinvoq |
| Alk-Abello, INC | $198.40 | 2020-2023 | Grastek, Odactra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $154.66 | 2019-2022 | |
| Boston Scientific Corporation | $102.63 | 2023 | |
| Sanofi-Aventis U.S. LLC | $99.99 | 2025 | |
| Genentech, INC. | $97.34 | 2019-2025 | Xolair |
| Circassia INC. | $96.40 | 2019-2021 | |
| Kaleo, INC. | $90.93 | 2020-2024 | Auvi-Q |
| Aimmune Therapeutics, INC. | $83.13 | 2021-2022 | |
| Organon LLC | $62.48 | 2025 | Vtama |
| Cardinal Health 200 LLC | $60.33 | 2019 | |
| Octapharma USA, INC. | $58.65 | 2021-2023 | Cutaquig |
| Pharming Healthcare, INC. | $55.28 | 2024-2025 | Ruconest |
| Lilly USA, LLC | $49.95 | 2024-2025 | Ebglyss |
| Ionis Pharmaceuticals, INC. | $48.57 | 2025 | Dawnzera |
| Merck Sharp & Dohme LLC | $44.35 | 2021-2023 | |
| Phadia US INC. | $42.69 | 2024 | Immunocap |
| Electromed, INC. | $40.83 | 2024 | Smartvest |
| Medline Industries Lp | $37.27 | 2024 | Medline Industries, INC. |
| Regeneron Pharmaceuticals, INC. | $29.60 | 2025 | Dupixent |
| Galderma Laboratories, L.P. | $29.42 | 2025 | Nemluvio |
| Ucb, INC. | $27.71 | 2021 | |
| Blueprint Medicines Corporation | $24.08 | 2023 | Ayvakit |
| Inspire Medical Systems, INC. | $23.11 | 2023 | Inspire |
| Cardiovascular Systems INC. | $22.89 | 2021 | |
| Dermavant Sciences, INC. | $22.69 | 2024 | Vtama |
| Kowa Pharmaceuticals America, INC. | $20.90 | 2025 | Zoryve |
| Greer Laboratories, INC. | $14.79 | 2019 | |
| Covis Pharma Gmbh | $14.48 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sam Ahn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.